Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares hit a new 52-week low on Tuesday . The stock traded as low as $8.99 and last traded at $9.04, with a volume of 121,847 shares. The stock had previously closed at $9.61.

Several brokerages have weighed in on COLL. Needham & Company LLC restated a “buy” rating and set a $30.00 target price (up from $28.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $26.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $28.25.

The company’s 50 day moving average is $11.47 and its 200-day moving average is $15.39. The firm’s market cap is $195.99 million.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. Equities research analysts predict that Collegium Pharmaceutical Inc. will post ($3.88) EPS for the current fiscal year.

In other news, Director John A. Fallon acquired 2,375 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The shares were purchased at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the transaction, the director now directly owns 2,375 shares in the company, valued at approximately $25,151.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.